Cutaneous T-cell lymphomas (CTCLs) are neoplasias of malignant T lymphocytes. In the early stages, treatment consists of phototherapy, local corticosteroids, or local chemotherapy. In more advanced stages, CTCL often becomes more resistant to standard therapies. In this prospective open multicenter trial, Quereux et al demonstrate the safety and efficacy of pegylated liposomal doxorubicin, 20 mg/m2, administered intravenously every 4 weeks. Higher doses increased the toxic effects but failed to increase the efficacy.